Takeda, Innovent-Lilly, Roche—Fierce Pharma Asia
Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a…
OX40, Roche-Sanegene, Daiichi—Fierce Pharma Asia
Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. Roche…
Enspryng falls short of Roche’s expectations in myasthenia gravis
Drug developers often try to spot tidbits of positive information from a failed clinical trial. But Roche is…
JPM26: Chugai chases new science and name recognition
The leaders of Chugai Pharmaceutical are tired of their company not getting its due. At the J.P. Morgan…
Roche axes 4 Chugai solid tumor assets in early-phase clear-out
Roche has dropped five Chugai candidates from its clinical pipeline, echoing actions the Japanese business took earlier this…
Roche’s Chugai inks Swiss ADC deal potentially worth over $780M
Roche’s Chugai Pharmaceutical is starting off its centennial year by spending some Swiss cheese. The Japanese unit is…
Swiss-Japanese ADC player Araris expands Chugai pact with $780m licensing agreement
Araris Biotech AG has concluded a research collaboration and option-to-license agreement with Chugai Pharmaceutical. The collaboration, launched around…